Investigational tinnitus drug shows promise in Phase 1/2 study

Neurotology drug developer Otonomy (NSDQ:OTIC) has announced that its OTO-313 drug appeared to reduce tinnitus severity in some participants in a small study.

In the study, summarized in Otology & Neurotology, patients with moderate to severe unilateral tinnitus received intratympanic administration of the drug or placebo.

Six OTO-313 recipients out of 14 (43%) showed a meaningful improvement in Tinnitus Functional Index score at weeks four and eight of the study. Conversely, 13% of placebo recipients showed the same level of improvement.

Patients who responded to the drug reported reductions in tinnitus loudness and distress.

The study also found that OTO-313 was well-tolerated, with adverse events greater in placebo recipients.

OTO-313 is a formulation of the selective N-methyl-D-aspartate (NMDA) receptor antagonist gacyclidine.

“Publication of these positive clinical results is an important milestone for the millions of people…

Read more
  • 0